PF-06305591 dihydrate

• CAT Number: I045583
• CAS Number: 2703582-76-5
• Molecular Formula: C15H26N4O3
• Molecular Weight: 310.39
• Purity: ≥95%
• Synonyms: (2R,3S)-3-amino-3-(6-tert-butyl-1H-benzimidazol-2-yl)-2-methylpropanamide;dihydrate
• InChI: InChI=1S/C15H22N4O.2H2O/c1-8(13(17)20)12(16)14-18-10-6-5-9(15(2,3)4)7-11(10)19-14;;/h5-8,12H,16H2,1-4H3,(H2,17,20)(H,18,19);2*1H2/t8-,12+;;/m1../s1
• InChIKey: GDSIVFNMVSHSPL-KHEMJLMASA-N
• SMILES: CC(C(C1=NC2=C(N1)C=C(C=C2)C(C)(C)C)N)C(=O)N.O.O

PF-06305591 dihydrate (Cat No.: I045583) is a selective, orally bioavailable inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme involved in the hydrolysis of oxidized phospholipids and the generation of pro-inflammatory mediators. By blocking Lp-PLA2 activity, PF-06305591 reduces vascular inflammation and oxidative stress, making it a valuable research tool in cardiovascular disease studies. It has been investigated for its potential in atherosclerosis and related metabolic disorders. The dihydrate form improves stability and handling, supporting its use in preclinical pharmacology and biochemical research.

Reference

[1]. Brown AD, et al. The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain. Bioorg Med Chem. 2019 Jan 1;27(1):230-239.
[Content Brief]